Agenus INC

Agenus Inc. announced a private placement raising over $85 million, with potential for up to $340 million, to fund its Phase 3 ROBBIN trial for neoadjuvant BOT+BAL in MSS colon cancer.

Agenus Inc. has amended terms on existing notes and extended the expiration dates of several series of warrants, while also issuing new warrants.

Agenus Inc. announced first quarter 2026 financial results, highlighting progress in its BOT+BAL program, including Phase 3 trial enrollment and a strategic collaboration with Zydus.

Agenus Inc. and its executives achieved a complete dismissal of a putative securities class action lawsuit in federal court.

Agenus Inc. announced its BOT+BAL immunotherapy program advanced to global Phase 3, expanded early access programs, and recognized initial revenues, alongside its Q4 and full year 2025 financial results.

Agenus Inc. announced the closing of its strategic collaboration with Zydus Lifesciences, securing $141 million in capital and manufacturing capacity to advance its BOT+BAL immunotherapy program.

Agenus Inc. announced its first-quarter 2026 financial results, highlighting a substantial increase in cash reserves driven by strategic collaborations and asset sales, alongside a significant reduction in operating expenses.

Agenus Inc. reported a net income of $63.86 million for Q3 2025, driven by a significant gain from the deconsolidation of MiNK Therapeutics and reduced operating expenses, despite ongoing liquidity concerns.

Agenus Inc. reported a reduced net loss for Q2 2025 but faces substantial doubt about its ability to continue as a going concern, despite a pending asset sale and equity investment.

Agenus Inc. announces its Q1 2025 financial results, highlighting a net loss, decreased revenue, and substantial doubt about its ability to continue as a going concern.

Agenus Inc. reported its third quarter 2024 results, highlighting increased non-cash royalty revenue but also significant operating losses and concerns about its ability to continue as a going concern.

Agenus Inc. reports a net loss of $115.1 million for the six months ended June 30, 2024, while highlighting strategic partnerships and pipeline advancements.

Agenus Inc. reports significantly reduced net losses and improved cash flow in 2025, bolstered by a strategic manufacturing facility sale and promising clinical data for its lead immunotherapy.

Agenus Inc. outlines its 2024 financial results and strategic realignment, focusing on the development and commercialization of its botensilimab/balstilimab program.

Agenus Inc.'s 2023 annual report highlights its focus on immuno-oncology, strategic partnerships, and the advancement of its lead drug candidates.

Garo H Armen, See Remarks and a Director of Agenus Inc, received 4,852 shares of common stock on July 10, 2026.

Agenus Inc. director Thomas L. Harrison acquired 8,547 shares of common stock through a board compensation policy.

Timothy Wright, a Director at Agenus Inc., acquired 2,267.765 Deferred Stock Units on July 1, 2026, under the company's Amended and Restated Directors' Deferred Compensation Plan.

Garo H. Armen, Director and Officer of Agenus Inc., acquired 5,364 shares of common stock valued at $3.03 per share, with salary paid in stock.

Garo H. Armen, Director and Officer of Agenus Inc., received 4,925 shares of common stock valued at $3.30 per share as compensation for his salary.

Agenus Inc. reports that Garo H. Armen, Director and Officer, received 4,644 shares of common stock valued at $3.50 per share as compensation for his salary.

Agenus Inc. outlines 2025 clinical progress, a strengthened balance sheet, and key equity proposals for the 2026 Annual Meeting.

Agenus Inc. is seeking stockholder approval to significantly expand its equity incentive plan and implement a one-time option exchange program to address challenges stemming from a negative FDA recommendation, stock price decline, and ongoing SEC investigation.

Agenus Inc. files an amendment to its definitive proxy statement to correct the number of outstanding common stock shares as of the record date.

Agenus is asking stockholders to approve amendments to its equity incentive plans and a one-time option exchange to enhance employee retention and align interests amid financial challenges.

Agenus Inc. is asking stockholders to approve amendments to its equity incentive plan and directors' deferred compensation plan at the upcoming annual meeting.

Agenus Inc. has amended its proxy statement to clarify the voting requirements for the proposed reverse stock split at the upcoming Special Meeting of Stockholders.

Zydus Lifesciences and its affiliates have acquired a 5.9% stake in AGENUS INC for $16 million, initiating a strategic collaboration and licensing deal.

RA Capital Management, L.P. and its affiliates have reported beneficial ownership of 9.9% of Agenus Inc.'s common stock.

Multiple entities and an individual have reported beneficial ownership of Agenus Inc. common stock, totaling 9.99% as of July 13, 2026.

The Vanguard Group has filed an amended Schedule 13G, reporting 0% beneficial ownership in Agenus Inc. following an internal realignment.

The Vanguard Group has disclosed an 8.06% beneficial ownership stake in Agenus Inc., holding 2,569,533 shares of common stock.

The Vanguard Group has filed an amended Schedule 13G, revealing a 9.23% beneficial ownership stake in Agenus Inc.'s common stock.

BlackRock, Inc. has filed an amended Schedule 13G, disclosing a 1.8% beneficial ownership stake in AGENUS INC's common stock as of June 30, 2025.